Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Share-based Compensation (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Share-based Compensation data on record, last reported at -$1.4 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 1550.94% year-over-year to -$1.4 million; the TTM value through Sep 2025 reached $1.3 million, up 39.36%, while the annual FY2024 figure was $1.1 million, 131.41% up from the prior year.
  • Share-based Compensation reached -$1.4 million in Q3 2025 per COEP's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.5 million in Q1 2022 and bottomed at -$3.5 million in Q2 2022.
  • Average Share-based Compensation over 4 years is $198789.8, with a median of $128510.0 recorded in 2023.
  • The widest YoY moves for Share-based Compensation: up 516.92% in 2025, down 1550.94% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at -$3.5 million in 2022, then soared by 103.63% to $128510.0 in 2023, then skyrocketed by 133.16% to $299631.0 in 2024, then plummeted by 569.17% to -$1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were -$1.4 million in Q3 2025, $1.8 million in Q2 2025, and $597731.0 in Q1 2025.